Assessing the Benefit–risk of New Treatments Using Generalised Pairwise Comparisons: The Case of Erlotinib in Pancreatic Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2015.55
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy